证券代码： 301580 证券简称：爱迪特 公告编号： 2024-021 2、本次股东大会不涉及变更以往股东大会已通过的决议。 爱迪特（秦皇岛）科技股份有限公司 2024 年第四次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会不存在否决议案的情形。 3、本次股东大会对中小投资者进行单独计票。 一、会议召开和出席情况 爱迪特（秦皇岛）科技股份有限公司（以下简称"公司"）2024 年第四次 临时股东大会（以下简称"股东大会"）现场会议于2024年9月18日下午14:30 在河北省秦皇岛市经济技术开发区都山路 9 号公司二楼会议室召开；同时使用 深圳证券交易所交易系统网络投票于 2024年 9月 18日交易时间接受网络投票， 即9:15-9:25，9:30-11:30和13:00-15:00；使用深圳证券交易所互联网投票系统于 2024 年 9 月 18 日 9:15-15:00 期间接受网络投票。 股东出席的总体情况：出席本次股东大会的股东及股东的委托代理人共计 93 人，代表公司有表决权的股份 26,658,1 ...

证券代码：301580 证券简称：爱迪特 爱迪特（秦皇岛） 科技股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | --- | |-----------------------------|---------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|--------|--------------| | | | | 编号： | 2024-006 | | | □特定对象调研 | □分析师会议 | | | | 投资者关系 | □媒体采访 □业绩说明会 | | | | | 活动类别 | □新闻发布会 | ☑ 路演活动 | | | | | □现场参观 | | | | | | □其他 | （请文字说明其他活 ...

证券代码：301580 证券简称：爱迪特 爱迪特（秦皇岛） 科技股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | --- | |--------------------------|----------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Financial Performance - The company reported a revenue of 500 million RMB for the first half of 2024, representing a 15% increase compared to the same period last year[2]. - The company's operating revenue for the reporting period reached ¥414,434,257.54, representing a 16.74% increase compared to ¥354,997,373.78 in the same period last year[13]. - Net profit attributable to shareholders was ¥76,789,371.20, up 21.41% from ¥63,246,939.98 year-on-year[13]. - The net cash flow from operating activities was ¥32,745,614.35, reflecting a 15.90% increase from ¥28,254,447.11 in the previous year[13]. - The gross margin for dental restoration materials increased from 57.17% to 60.36% compared to the same period last year[25]. - The company reported a total of ¥447,822.84 in non-recurring losses, primarily due to other operating income and expenses[17]. - The company reported a non-recurring profit of ¥77,237,194.04, which is a 36.46% increase from ¥56,602,182.36 in the same period last year[13]. - The company’s operating revenue reached ¥414,434,257.54, an increase of 16.74% compared to the previous year[54]. - The company reported a total comprehensive income of ¥77,137,544.87 for the first half of 2024, which includes a significant increase in retained earnings[151]. User Growth and Market Expansion - User data indicates a growth in active users by 20%, reaching a total of 1.2 million users[3]. - The company is expanding its market presence in Southeast Asia, targeting a 25% market share in the region by 2025[3]. - The company completed the acquisition of Korean company Wolan Holdings in May 2024, aiming to expand its presence in the Chinese implant market[25]. - The company is recognized as one of the top two domestic brands in dental crown materials, establishing a strong reputation in the industry[23]. - The company is focusing on improving service quality in the implant business and strengthening its core technology and brand awareness[21]. Research and Development - Research and development expenses increased by 30%, totaling 80 million RMB, focusing on advanced dental technologies[3]. - The company has established a comprehensive R&D system, leading to rapid increments in new products and innovations in dental restoration materials and digital equipment[34]. - The company is actively developing new products in orthodontics, prevention, and treatment, contributing to its business growth[25]. - R&D investment accounted for 5.15% of the company's operating revenue during the reporting period, with 27 patents applied for[82]. - The company has established a joint laboratory with Peking University School of Stomatology to conduct research on dental biomimetic non-metal materials[82]. Strategic Initiatives - A strategic acquisition of a local dental technology firm is underway, expected to enhance product offerings and increase market competitiveness[3]. - The company has implemented a production model combining sales-based production and stock preparation to balance order delivery and inventory turnover efficiency[29]. - The company has adopted a direct sales and distribution model, focusing on domestic clients while collaborating with core distributors for international sales[31]. - The company is focusing on a customer-centric marketing system, enhancing resource investment to manage leads and opportunities effectively[38]. - The company is exploring potential acquisitions to enhance its market position, with a focus on technology firms that align with its strategic goals[181]. Financial Position and Assets - Total assets at the end of the reporting period amounted to ¥2,246,022,533.54, a significant increase of 73.88% from ¥1,291,720,904.45 at the end of the previous year[13]. - The net assets attributable to shareholders increased by 78.96% to ¥1,916,891,144.91 from ¥1,071,142,657.12 year-on-year[13]. - The company's total liabilities increased to ¥239,506,490.45 in the first half of 2024, up from ¥194,616,629.23 in the previous year, indicating a rise of 23.1%[141]. - The total equity of the company reached ¥1,976,265,981.52, a significant increase from ¥1,118,831,586.99 in the first half of 2023, marking a growth of 76.8%[141]. - The company reported a significant increase in intangible assets to ¥90,169,739.05 from ¥7,493,837.81, marking a growth of approximately 1103.0%[135]. Compliance and Regulatory Matters - The company is committed to compliance with regulatory requirements for medical device disclosures, ensuring transparency in operations[38]. - The company has registered multiple dental products with FDA, including orthodontic appliances and desensitizing agents, with registration periods ranging from 2019 to 2029[42]. - The company faces compliance risks due to varying regulations in different countries for medical devices, necessitating regular compliance training for employees[81]. - The company emphasizes the importance of understanding international patent laws to avoid disputes and has implemented strict confidentiality measures[84]. Sustainability and Social Responsibility - The management emphasizes a commitment to sustainability and social responsibility initiatives in its operations[3]. - The company completed the Smile Plan initiative in Mexico, providing free digital dentures to multiple edentulous patients[98]. - A total of 27 special education students received free dental treatment services during the reporting period[98]. - The company emphasizes environmental responsibility by promoting energy-saving practices and reducing carbon emissions through various initiatives[93]. - The company maintains a strong commitment to protecting employee rights, ensuring compliance with labor laws, and providing social insurance benefits[95]. Shareholder and Corporate Governance - The company held two shareholder meetings in 2024, with 100% investor participation, discussing key proposals including extending the validity period for the initial public offering[88][89]. - The company plans not to distribute cash dividends or issue bonus shares for the half-year period[91]. - There were no changes in the board of directors, supervisors, or senior management during the reporting period[90]. - The company has not engaged in any significant asset or equity acquisitions or sales during the reporting period[105]. - The total number of shares increased from 57,088,145 to 76,117,527 after the issuance of 19,029,382 new shares[119].

企业 | 非经营性资金占用 | 资金占用方名称 | 占用方与 上市公司 | 上市公司核 | 2024 年期初 | 2024 | 半年度占 | 20XX 年度占 | 2024 半年度 | 2024 | 半年度 | 占用形 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 的关联关 | 算的会计科 | 占用资金余 | | 用累计发生金 | 用资金的利息 | 偿还累计发 | 期末占用资 | | 成原因 | | | | | 系 | 目 | 额 | | 额（不含利息） | （如有） | 生金额 | 金余额 | | | | | 控股股东、实际控制 | | | | | | | | | | | | | | 人及其附属企业 | | | | | | | | | | | | | | 小计 | - | - | - | | | | | | | | | | | 前控股股东、实际控 | | | | | | | | | | | | | | 制人及其附属企业 | | | | | | | | | | | | ...

关于使用自有资金支付募投项目所需部分资金并以募集资金等额置 换的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 爱迪特（秦皇岛）科技股份有限公司（以下简称"公司"）于 2024 年 8 月 29 日召开公司第三届董事会第十六次会议、第三届监事会第十三次会议，审议 通过了《关于使用自有资金支付募投项目所需部分资金并以募集资金等额置换 的议案》，同意公司在募投项目的实施期间，根据实际需要并经相关审批后， 预先使用自有资金支付募投项目部分款项，之后定期以募集资金等额置换。具 体内容如下： 一、募集资金基本情况 经中国证券监督管理委员会出具的《关于同意爱迪特（秦皇岛）科技股份 有限公司首次公开发行股票注册的批复》（证监许可〔2023〕2615 号）同意注 册，公司首次公开发行人民币普通股（A 股）股票 1,902.9382 万股（以下简称 "本次发行"），每股发行价格为人民币 44.95 元，募集资金总额为人民币 85,537.07 万元，扣除各项发行费用后，募集资金净额为人民币 76,131.57 万元。 上述募集资金已于 2024 年 6 月全部到位，容诚会 ...

爱迪特（秦皇岛）科技股份有限公司（以下简称"公司"）将于 2024 年 8 月 30日在巨潮资讯网（www.cninfo.com.cn）披露《2024年半年度报告》。为加 强与投资者交流，使投资者更全面、深入地了解公司经营情况，公司将于 2024 年 9 月 3 日（星期二）召开 2024 年中期业绩发布会。 一、业绩说明会安排 1、召开时间：2024 年 9 月 3 日（星期二）15:30-16:30 2、召开方式：线上会议 关于召开 2024 年中期业绩发布会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 证券代码： 301580 证券简称：爱迪特 公告编号： 2024-012 爱迪特（秦皇岛）科技股份有限公司 3、交流内容：公司将针对 2024 年半年度经营成果、财务指标等与投资者 进行交流，并对投资者普遍关注的问题进行回答。 4、出席人员：董事长、总经理李洪文先生；董事会秘书、副总经理郜雨女 士；财务总监孔祥乾先生；独立董事贾国军先生；董事王雪松女士。（具体以 当天实际参会人员为准） 5、报名及参会方式： （1）网络端报名参会：https:// ...

爱迪特（秦皇岛）科技股份有限公司 关于使用募集资金置换预先投入募投项目及已支付发行费用的自筹 资金的公告 证券代码： 301580 证券简称：爱迪特 公告编号： 2024-011 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 爱迪特（秦皇岛）科技股份有限公司（以下简称"公司"）于 2024 年 8 月 15 日召开公司第三届董事会第十五次会议、第三届监事会第十二次会议，审议 通过了《关于使用募集资金置换预先投入募投项目及已支付发行费用的自筹资 金的议案》，同意公司使用募集资金人民币 7,632.27 万元置换预先投入募投项 目及已支付发行费用的自筹资金。具体内容如下： 一、募集资金基本情况 经中国证券监督管理委员会出具的《关于同意爱迪特（秦皇岛）科技股份 有限公司首次公开发行股票注册的批复》（证监许可〔2023〕2615 号）同意注 册，公司首次公开发行人民币普通股（A 股）股票 1,902.9382 万股（以下简称 "本次发行"），每股发行价格为人民币 44.95 元，募集资金总额为人民币 85,537.07 万元，扣除各项发行费用后，募集资金净额为人民币 ...

爱迪特（秦皇岛）科技股份有限公司（以下简称"公司"）第三届董事会 第十五次会议于 2024 年 8 月 15 日在秦皇岛市经济技术开发区都山路 9 号公司会 议室以现场与通讯方式相结合的方式召开。会议通知于 2024 年 8 月 9 日以电子 邮件的方式向全体董事和相关与会人员发出。会议由董事长李洪文先生主持。 会议应出席董事 9 人，实际出席董事 9 人。公司全体监事和高级管理人员列席 会议。会议召集及召开程序符合《公司法》等法律、法规、规范性文件和《公 司章程》的有关规定。 二、董事会会议审议情况 （一）审议通过《关于使用募集资金置换预先投入募投项目及已支付发行 费用的自筹资金的议案》 证券代码： 301580 证券简称：爱迪特 公告编号： 2024-009 爱迪特（秦皇岛）科技股份有限公司 第三届董事会第十五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 表决结果：9 票赞成；0 票反对；0 票弃权；0 票回避。 三、备查文件 爱迪特（秦皇岛）科技股份有限公司第三届董事会第十五次会议决议。 特此公告。 爱迪特（秦皇 ...

中信建投证券股份有限公司 关于爱迪特（秦皇岛）科技股份有限公司 使用募集资金置换预先已投入募投项目及已支付发行费用 的自筹资金的核查意见 中信建投证券股份有限公司（以下简称"中信建投证券"或"保荐人"） 作为爱迪特（秦皇岛）科技股份有限公司（以下简称"爱迪特"或"公司"） 首次公开发行股票并在创业板上市的保荐人，根据《证券发行上市保荐业务管 理办法》《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管 要求》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自 律监管指引第 2 号——创业板上市公司规范运作》等有关规定，对公司使用募 集资金置换预先已投入募投项目及已支付发行费用的自筹资金事项进行了核查， 具体情况如下： 一、募集资金基本情况 经中国证券监督管理委员会出具的《关于同意爱迪特（秦皇岛）科技股份 有限公司首次公开发行股票注册的批复》（证监许可〔2023〕2615 号）同意注 册，公司首次公开发行人民币普通股（A 股）股票 1,902.9382 万股（以下简称 "本次发行"），每股发行价格为人民币 44.95 元，募集资金总额为人民币 85,537.07 万元，扣除各项发行费用后 ...